Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 130Brain Neoplasms 115Prostatic Neoplasms 101Neoplasm Metastasis 83Lung Neoplasms 72Carcinoma, Hepatocellular 71Pancreatic Neoplasms 67Breast Neoplasms 48Melanoma 44Carcinoma, Renal Cell 36Neoplasms 33Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Glioblastoma 24Liver Neoplasms 20Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Sarcoma 13Glioma 12Kidney Neoplasms 11Urinary Bladder Neoplasms 9Recurrence 9Gliosarcoma 8Ovarian Neoplasms 7Adenocarcinoma of Lung 7Adenocarcinoma 7Prostate Cancer Metastatic 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Uveal Melanoma 5

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Radiotherapy, Intensity-Modulated 11Paclitaxel 11Carboplatin 11Fluorouracil 10Biopsy 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Drug Therapy 9Taxes 7Surgical Procedures, Operative 7Celecoxib 7X-Rays 6Standard of Care 6Sentinel Lymph Node Biopsy 6Surveys and Questionnaires 5Nivolumab 5cemiplimab 4Metformin 4Fluorodeoxyglucose F18 4Docetaxel 4Chemoradiotherapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Mouth Neoplasms × Radiosurgery × Clear all
NCT07156227 2026-06-03

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡